Cardiac Rhythm Disease Management (CRDM) Business Overview

CRDM accounted for $4.9 billion, or 37%, of Medtronic's $13.5 billion in revenue in FY2008

FY2008 Global Revenue
CRDM accounted for $4.9 billion, or 37%, of Medtronic's $13.5 billion in revenue in FY2008.

CRDM is the oldest and largest of Medtronic's business units. Our work in heart rhythm therapies dates back to 1957, when co-founder Earl Bakken developed the first wearable heart pacemaker to treat abnormally slow heart rates. Since then, we've expanded our expertise in electrical stimulation to treat other cardiac rhythm diseases. We've also moved into more overall disease management by adding diagnostic and monitoring capabilities to many of our devices.

Today, CRDM's primary product lines are:

Implantable pacemakers and accessories for treating hearts that beat too slowly. We also provide an insertable diagnostic monitor that can help doctors determine if unexplained fainting may be the result of an abnormally slow heart rhythm.

Implantable cardioverter-defibrillators (ICDs) for monitoring and correcting heart rates that are dangerously out of rhythm.

Implantable cardiac resynchronisation therapy devices (CRTs), often combined with defibrillators (CRT-Ds), that synchronise the beating of the left and right heart chambers to optimise pumping capability for persons with heart failure.

Monitoring systems that link wearers of implantable devices with their physicians via the Internet. This allows physicians to perform a complete analysis of all the data stored in a patient's device, similar to what would be viewed in an in-office visit. For some people, this may mean fewer in-office visits, and less time traveling to and from the clinic.

Last updated: 27 Sep 2010

Section Navigation

Additional information


Enduring Partnerships


Our history of working closely with cardiologists and other medical professionals began with our very first device.